Results
MAY, COMMON COLD
In the winter period of 2019, between January and April, 701 eligible subjects were recruited and randomly assigned to the ColdZyme group (n = 351) or the placebo group (n = 350). The last subject completed the study in May 2019. Of the 701 subjects, 438 (62.5%) subjects developed symptoms of common cold, and all 438 started study treatment for their common cold episode (n = 220 in the ColdZyme group and n = 218 in the placebo group). Two subjects of the AST (n = 438) were excluded from the FAS (n = 436), as seen in 